{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:27:11Z","timestamp":1786991231062,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":471,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"crossref","award":["K08 HL094375"],"award-info":[{"award-number":["K08 HL094375"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AstraZeneca"},{"name":"Merck & Co."},{"name":"AstraZeneca"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol-Myers Squibb"},{"name":"AstraZeneca"},{"name":"AstraZeneca"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.jacc.2011.12.035","type":"journal-article","created":{"date-parts":[[2012,4,16]],"date-time":"2012-04-16T19:46:58Z","timestamp":1334605618000},"page":"1521-1528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["On-Treatment Non\u2013High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy"],"prefix":"10.1016","volume":"59","author":[{"given":"Samia","family":"Mora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Glynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Matthijs","family":"Boekholdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2011.12.035_bib1","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2011.12.035_bib2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/eurheartj\/ehm316","volume":"28","author":"Graham","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2011.12.035_bib3","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2011.12.035_bib4","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2011.12.035_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3132\/dvdr.2008.046","article-title":"The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient","volume":"5","author":"Fruchart","year":"2008","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jacc.2011.12.035_bib6","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2011.12.035_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(10)60713-1","article-title":"High density lipoprotein cholesterol and risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the randomized, placebo controlled JUPITER trial","volume":"376","author":"Ridker","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2011.12.035_bib8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(10)61021-5","article-title":"Dissociating HDL cholesterol from cardiovascular risk","volume":"376","author":"Hausenloy","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2011.12.035_bib9","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-2796.2006.01646.x","article-title":"Apolipoproteins AI and B as therapeutic targets","volume":"259","author":"Charlton-Menys","year":"2006","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacc.2011.12.035_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2796.2006.01616.x","article-title":"Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person\/ten-country panel","volume":"259","author":"Barter","year":"2006","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacc.2011.12.035_bib11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2796.2006.01643.x","article-title":"The apoB\/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy\u2014a review of the evidence","volume":"259","author":"Walldius","year":"2006","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacc.2011.12.035_bib12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/01.CIR.101.5.477","article-title":"Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TexCAPS)","volume":"101","author":"Gotto","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2011.12.035_bib13","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00125-008-1176-8","article-title":"Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"52","author":"Charlton-Menys","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2011.12.035_bib14","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2011.12.035_bib15","doi-asserted-by":"crossref","first-page":"33A","DOI":"10.1016\/j.amjcard.2005.11.014","article-title":"Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)\u2014can C-reactive protein be used to target statin therapy in primary prevention?","volume":"97 Suppl","author":"Mora","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2011.12.035_bib16","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.amjcard.2007.09.072","article-title":"Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein","volume":"100","author":"Ridker","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2011.12.035_bib17","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2011.12.035_bib18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1373\/clinchem.2008.120642","article-title":"Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study","volume":"55","author":"Glynn","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2011.12.035_bib19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2011.12.035_bib20","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCULATIONAHA.109.906479","volume":"121","author":"Mora","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2011.12.035_bib21","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/01.CIR.97.15.1453","article-title":"Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)","volume":"97","author":"Pedersen","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2011.12.035_bib22","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/hc1002.105136","article-title":"Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?","volume":"105","author":"Simes","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2011.12.035_bib23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/ATVBAHA.108.181735","article-title":"Prognostic utility of apoB\/AI, total cholesterol\/HDL, non-HDL cholesterol, or hsCRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT TIMI 22","volume":"29","author":"Kausik","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2011.12.035_bib24","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/01.CIR.97.15.1446","article-title":"Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial","volume":"97","author":"Sacks","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2011.12.035_bib25","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.CIR.97.15.1440","article-title":"Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)","volume":"97","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2011.12.035_bib26","doi-asserted-by":"crossref","first-page":"b92","DOI":"10.1136\/bmj.b92","article-title":"Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis","volume":"338","author":"Briel","year":"2009","journal-title":"BMJ"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109712005530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109712005530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:51:38Z","timestamp":1760014298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109712005530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":26,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0735109712005530"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2011.12.035","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On-Treatment Non\u2013High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2011.12.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}